Cipla Limited
CIPLA
Hisse Senetlerindeki Sıralama
#1812
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Hisse Fiyatı
$14.61
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$11.81B
Değişim (1 gün)
-0.11%
Değişim (1 yıl)
-21.65%
Ülke
IN
Ticaret Cipla Limited (CIPLA)
Kategori
Healthcare
Cipla Limited (CIPLA) için P/B oranı
October 2026 itibarıyla P/B oranı TTM: 3.11
Cipla Limited şirketinin en son mali raporları ve hisse fiyatına göre, mevcut P/B oranı (TTM) 3.11'dir. 2024 yılının sonunda şirketin P/B oranı 4.53 idi.
Cipla Limited için P/B oranı geçmişi 2004 - 2026 arası
Her yılın sonunda P/B oranı
| Yıl | P/B Oranı | Değiştir |
|---|---|---|
| 2026 (TTM) | 3.11 | -16.73% |
| 2025 | 3.74 | -17.41% |
| 2024 | 4.53 | 45.93% |
| 2023 | 3.10 | -21.21% |
| 2022 | 3.94 | 9.87% |
| 2021 | 3.59 | 65.87% |
| 2020 | 2.16 | -23.32% |
| 2019 | 2.82 | -13.48% |
| 2018 | 3.26 | -14.25% |
| 2017 | 3.80 | 6.45% |
| 2016 | 3.57 | -32.58% |
| 2015 | 5.30 | 86.12% |
| 2014 | 2.85 | -16.93% |
| 2013 | 3.43 | 6.81% |
| 2012 | 3.21 | -17.22% |
| 2011 | 3.87 | -14.35% |
| 2010 | 4.52 | 14.98% |
| 2009 | 3.93 | -13.61% |
| 2008 | 4.55 | -19.79% |
| 2007 | 5.68 | -43.30% |
| 2006 | 10.01 | 102.81% |
| 2005 | 4.94 | -11.35% |
| 2004 | 5.57 | 0.00% |
Benzer şirketler veya rakipler için P/B oranı
| Şirket | P/B Oranı | P/B Oranı Farkı | Ülke |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 61.86% |
IN
|
